MIGS: What Is It and What Outflow Pathways Does It Target? -

Name: MIGS: What Is It and What Outflow Pathways Does It Target?
Uploaded: 2021-03-22T04:00:00+00:00
Duration: 39 min
Description: In this episode, faculty define minimally invasive glaucoma surgier (MIGS) and describe how MIGS procedures target different outflow pathways.Supported by

Media formats available:

Details

Presenters

Download PDF

Overview
In this episode, faculty define minimally invasive glaucoma surgier (MIGS) and describe how MIGS procedures target different outflow pathways.
Supported by an unrestricted educational grant from Sight Sciences.
Learning Objectives
Describe the impact of resistance in different outflow pathways on glaucoma patient outcomes Identify the efficacy levels, short-term complication rates and long-term tissue removal risks of various glaucoma surgical procedures
Accreditation
Sponsored by:

Evolve is an approved COPE Administrator. This course is COPE approved for .5 hours of CE credit for optometrists.
COPE Course ID: 71826-GL
COPE Activity ID: 121381
Faculty and Disclosures
Kristopher May, OD
Coldwater Vision Center
Coldwater, MS

Deborah Ristvedt, DO
Ophthalmologist Surgeon
Vance Thompson Vision
Bozeman, MT

Leslie O’Dell, OD, FAAO
Clinical Director
Medical Optometry America
York, PA

Justin Schweitzer, OD, FAAO
Vance Thompson Vision
Sioux Falls, SD

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Kristopher May, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, and Sight Sciences. Speaker’s Bureau: Alcon, Bausch + Lomb, and Sight Sciences.
Deborah Ristvedt, DO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Glaukos, and Sight Sciences. Grant/Research Support: Allergan. Speaker’s Bureau: Alcon, and Glaukos.
Leslie O’Dell, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Allergan, Bausch + Lomb, Dompe, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Oyster Point, Pharma, Sun Pharmaceutical Industries, Sight Sciences, and Tarsus. Speaker's Bureau: Allergan, Johnson & Johnson Vision, and Sight Sciences.
Justin Schweitzer, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Dompé, EyePoint, Horizon, Ocular Therapeutix, and Reichert. Grant/Research Support: Glaukos. Speaker’s Bureau: Aerie, Alcon, Allergan, Bausch + Lomb, Glaukos, Quidel, Sight Sciences, and Sun Pharmaceutical Industries. Share/Stockholder: Equinox.
The Evolve Medical Education or The Fundingsland Group staff and planners have no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group or Sight Sciences.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 03/22/2021
Expiration Date: 12/30/2022

Leslie O’Dell, OD, FAAO

Guest

Justin Schweitzer, OD, FAAO

Guest

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Catching Demodex in the Act
Catching Demodex in the Act
MinuteCE®
Catching Demodex in the Act
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit
At the Intersection of DB, DED, MGD, and Other Forms of Blepharitis
At the Intersection of DB, DED, MGD, and Other Forms of Blepharitis
MinuteCE®
At the Intersection of DB, DED, MGD, and Other Forms of Blepharitis
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit
The Neverending Journey: A 66-Year-Old Patient Who Has Undergone Several Rounds of Tea Tree Oil–Based Treatment
The Neverending Journey: A 66-Year-Old Patient Who Has Undergone Several Rounds of Tea Tree Oil–Based Treatment
MinuteCE®
The Neverending Journey: A 66-Year-Old Patient Who Has Undergone Several Rounds of Tea Tree Oil–Based Treatment
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit
Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
MinuteCE®
Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit